Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Brasseur, Mathilde ^a   Heurgué Berlot, Alexandra ^a   Barbe, Coralie ^a   Brami, Cloé ^a   Rey, Jean Baptiste ^b,c   Vella Boucaud, Juliette ^d   Dabouz, Fadia ^a   Deslée, Gaëtan ^d   Grange, Florent ^a   Volet, Julien ^a   Bouché, Olivier ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b Institut de Cancérologie Jean Godinot   (France)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^d HÔPITAL MAISON BLANCHE   (France)

Author keywords

Chemotherapy; HBV screening; Hepatitis B virus; Hepatitis C virus; Reactivation; Solid tumors

Indexed keywords

CAPECITABINE; DOXORUBICIN; ENTECAVIR; EPIRUBICIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; OXALIPLATIN; PEMETREXED; STREPTOZOCIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SENSIBILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEROPREVALENCE; SKIN CANCER; SOLID TUMOR; STOMACH CANCER; VIRUS LOAD; VIRUS REACTIVATION; FRANCE; MIDDLE AGED; NEOPLASMS; PREVALENCE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HEPATITIS B; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84951752204     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-2033-z     Document Type: Article

References (30)

1. Institut de Veille Sanitaire (InVS). Prévalence des hépatites B et C en France en 2004. www.invs.sante.fr/publications/2006/prevalence:b_c/vhb_france:2004.pdf (2007, accessed 17 September 2014)
2. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182-8.
3. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299-307.
4. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347(8994):92-3.
5. Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83(6):1224-30.
6. Yeo W, Chan PKS, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70(4):553-61.
7. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306-11.
8. Ling WHY, Soe PP, Pang ASL, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108(10):1931-5.
9. Liver EAFTSOT. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85.
10. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol Baltim Md. 2009;50(3):661-2.
11. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531-61.
12. Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep. Cent. Dis. Control 2008; 57(RR-8):1-20.
13. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104-10.
14. Hwang JP, Fisch MJ, Lok AS-F, et al. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013;13:534.
15. Lee RSM, Bell CM, Singh JM, et al. Hepatitis B screening before chemotherapy: a survey of practitioners' knowledge, beliefs, and screening practices. J Oncol Pract Am Soc Clin Oncol. 2012;8(6):325-8. 1 p following 328.
16. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(19):3199-202.
17. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw JNCCN. 2012;10(11):1412-45.
18. Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2011;22 Suppl 6:vi59-63.
19. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999;81(1):69-74.
20. Kose S, Olmezoglu A, Gozaydin A, et al. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr. 2011;29(6):652-5.
21. Oguz A, Aykas F, Unal D, et al. Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy. Asian Pac J Cancer Prev APJCP. 2014;15(3):1411-4.
22. Institut de Veille Sanitaire (InVS). Prevalence, morbidity and mortality associated with chronic hepatitis B and C in the French hospitalized population (2004-2011). www.invs.sante.fr/beh/2014/12/pdf/2014_12_1.pdf (2013, accessed 17 September 2014)
23. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(24):3270-7.
24. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2004;15(11):1661-6.
25. Chang M-H. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007;12(3):160-7.
26. Institut de Veille Sanitaire (InVS). BEH 22/98 Stratégie de dépistage de l'hépatite C en population générale dans les centres d'examens de santé. Dispositif de veille sanitaire pour la coupe du monde de football, en 1998. www.invs.sante.fr/beh/1998/9822/beh_22_1998.pdf (1998, accessed 17 September 2014)
27. Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol. 2001;17(8):721-8.
28. McQuillan GM, Townsend TR, Johannes CB, et al. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am J Epidemiol. 1987;126(3):484-91.
29. Centers for Disease Control and Prevention DVH - Viral Hepatitis - Hepatitis Risk Assessment. www.cdc.gov/hepatitis/riskassessment/ (accessed 17 September 2014)
30. Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy. clinicaltrials.gov/show/NCT01970254 (accessed 17 September 2014)